CDK2 and prostate carcinoma: The LATS2 TS is suggested to function through inhibition of MDM2 resulting in stabilization of the TS TP53 (p53),25 as well as directly inhibiting the activity of the cyclinE/CDK2 complex.26 ZBTB7A has been shown to be a TS in prostate cancer as ZBTB7A activity results in increased RB1 stability.16 Our analysis of oncomotif-miRNA targets included miRNA target prediction algorithms that predict targets based on complementarity between the seed sequence of the miRNA and the 3' UTR of mRNAs as well as evolutionary conservation in the 3' UTR sequence.